Added to YB: 2026-09-17
Pitch date: 2026-09-15
ABOS [neutral]
Acumen Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
Market Cap
$201.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.17
P/E
-1.70
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Biotech Conference Coverage: Week 2, Day 1 — Part 1: Acumen Pharmaceuticals, Inc.
ABOS (quick overview): Acumen’s defining catalyst is Q4 2026 topline data from the 542-patient Phase II ALTITUDE-AD trial of sabirnetug in early Alzheimer’s. Acumen views roughly 30% slowing of cognitive decline as competitive with existing anti-amyloid therapies, but the real potential differentiator is an improved ARIA profile. A clear cognitive and functional signal plus favorable ARIA could raise strategic interest; weak efficacy or class-like safety would challenge the oligomer-selective thesis.
Read full article (1 min)